Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Relapsed AL Amyloidosis: early-phase trial registry

1 of 1 indexed Relapsed AL Amyloidosis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Relapsed AL Amyloidosis: 1 US clinical trial tracked, 1 recruiting.

Relapsed AL Amyloidosis is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Alexion Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition relapsed-al-amyloidosis

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Relapsed AL Amyloidosis (thi…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Relapsed AL Amyloidosis

Relapsed AL Amyloidosis lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Relapsed AL Amyloidosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Relapsed AL Amyloidosis is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Relapsed AL Amyloidosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

AZD0120 Drug
1 trials

US sites by state

Facility locations filed on Relapsed AL Amyloidosis trials. A trial with sites in several states counts in each.

Tennessee 1 trials
Ohio 1 trials
New York 1 trials
Missouri 1 trials
Minnesota 1 trials
Michigan 1 trials
Massachusetts 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Relapsed AL Amyloidosis page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed AL Amyloidosis condition card totals 1 registered trials; most-linked intervention AZD0120; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.